Onc Now
In this episode of Onc Now, EMJ speaks with Elizabeth Jaffee about the evolving landscape of cancer immunotherapy. She explores why pancreatic cancer has proved so challenging to treat, how therapeutic cancer vaccines could help harness the immune system, and the role of the tumour microenvironment in shaping treatment responses. Jaffee also discusses emerging biomarkers, promising treatment combinations, and the potential of personalised immunotherapy to improve patient outcomes.
Speaker bio:
Elizabeth Jaffee is Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA, and an internationally recognised expert in cancer immunology, therapeutic cancer vaccines, and pancreatic cancer. Her research focuses on harnessing the immune system to treat cancer, understanding the tumour microenvironment, and developing innovative immunotherapeutic strategies to improve outcomes for patients.
Timestamps:
00:00 – Introduction
00:48 – The Journey into Cancer Immunology
02:15 – Exploring the Frontiers of Cancer Research
08:28 – Overcoming Pancreatic Cancer Immunotherapy Challenges
11:19 – The Promise of Therapeutic Cancer Vaccines
13:40 – Predicting Responses to Cancer Immunotherapy
18:51 – Combining Treatments to Improve Outcomes
22:12 – From Laboratory Discoveries to Patient Care
25:10 – The Future of Cancer Immunotherapy
28:27 – Three Wishes for Cancer Immunotherapy
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Disclosure: TBC
Keywords: Biomarkers, cancer immunology, cancer immunotherapy, cancer prevention, immuno-oncology, oncology, pancreatic cancer, personalised medicine, therapeutic cancer vaccines, tumour microenvironment.
